National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

yttrium Y 90-edotreotide
A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:Y90-DOTA-tyr3-octreotide
yttrium Y 90 -DOTATOC
yttrium Y 90 SMT 487
yttrium Y 90-DOTA-tyr3-octreotide
US brand name:Y-90 OctreoTher



Previous:yttrium Y 90 monoclonal antibody BrE-3, yttrium Y 90 monoclonal antibody Hu3S193, yttrium Y 90 monoclonal antibody MN-14, yttrium Y 90 resin microspheres, yttrium Y 90-DOTA-chimeric monoclonal antibody cG250
Next:Z-360, Zactima, zalcitabine, Zanosar, Zarnestra

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov